Platelets are essential for clotting in the blood and maintenance of normal hemostasis.
Under pathologic conditions such as atherosclerosis, vascular injury often results in …

The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11
families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of …

ciation (AHA) convened a writing committee. The ACCF and AHA adhere to a rigorous policy
regarding relationships with industry and other entities (RWI) of authors and peer reviewers …

Inhibition of platelet aggregation can be achieved either by the blockade of membrane
receptors or by interaction with intracellular signalling pathways. Cyclic adenosine 3′, 5 …

The clinical pharmacology of antiplatelet drugs has been reviewed previously by the
European Society of Cardiology (ESC) Task force and by the 8th American College of Chest …

Primarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone
derivative that works through the inhibition of phosphodiesterase III and related increases in …

The P2Y 12 receptor is a key player in platelet activation and represents an effective
pharmacological target for the inhibition of platelet aggregation and prevention of …

Our knowledge of the mechanisms of platelet-mediated thrombosis has increased
dramatically over the last 40 years. This increased understanding has identified treatment …

Background: Patients undergoing percutaneous coronary intervention react differently to
antiplatelet drugs. Those with low responsiveness to clopidogrel have a higher risk of …

The platelet—an anucleate cell—is the bedrock of thrombosis, both physiologically and
pathologically. Antagonism of the P2Y12 receptor for ADP is one of several pathways …